The effect of marjoram (Origanum majorana) tea on the hormonal profile of women with polycystic ovary syndrome: A randomised controlled pilot study

Journal of Human Nutrition and Dietetics

Volumn 29, Issue 1, 2016, Pages 105-111

  Haj Husein, I ^a   Tukan, S ^a   Alkazaleh, F ^a  

^a UNIVERSITY OF JORDAN   (Jordan)

Author keywords

Androgens; Insulin resistance; Marjoram tea; Traditional medicine

Indexed keywords

ANDROGEN; ESTRADIOL; FOLLITROPIN; GLUCOSE BLOOD LEVEL; HERBAL TEA; INSULIN; LUTEINIZING HORMONE; PRASTERONE SULFATE; PROGESTERONE; TESTOSTERONE;

ADOLESCENT; ADULT; BLOOD; BODY MASS; BODY WEIGHT; CHEMISTRY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE BLOOD LEVEL; HERBAL TEA; HUMAN; INSULIN RESISTANCE; METABOLISM; ORIGANUM; PILOT STUDY; POLYCYSTIC OVARY SYNDROME; RANDOMIZED CONTROLLED TRIAL; WAIST CIRCUMFERENCE; YOUNG ADULT;

ADOLESCENT; ADULT; ANDROGENS; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; DEHYDROEPIANDROSTERONE SULFATE; DOUBLE-BLIND METHOD; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; INSULIN; INSULIN RESISTANCE; LUTEINIZING HORMONE; ORIGANUM; PILOT PROJECTS; POLYCYSTIC OVARY SYNDROME; PROGESTERONE; TEAS, HERBAL; TESTOSTERONE; WAIST CIRCUMFERENCE; YOUNG ADULT;

EID: 84955693423     PISSN: 09523871     EISSN: 1365277X     Source Type: Journal    
DOI: 10.1111/jhn.12290     Document Type: Article

References (34)

1. March WA, Moore VM, Willson KJ et al., (2010) The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 25, 544-551.
2. Allahbadia GN & Merchant R (2011) Polycystic ovary syndrome and impact on health. Middle East Fertil Soc J 16, 19-37.
3. Luque-Ramíreza M, San Millán JL & Escobar-Morreale HF (2006) Genomic variants in polycystic ovary syndrome. Clin Chim Acta 366, 14-26.
4. Baptiste CG, Battista MC, Trottier A et al., (2010) Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem 122, 42-52.
5. Franks S (2011) When should an insulin sensitizing agent be used in the treatment of polycystic ovary syndrome? Clin Endocrinol 74, 148-151.
6. Geller DH, Pacaud D, Gordon CM et al., (2011) State of the art review: emerging therapies: the use of insulin sensitizers in the treatment of adolescents with polycystic ovary syndrome (PCOS). Int J Pediatr Endocrinol 9, 1-19.
7. Vera RR & Chane-Ming J (1999) Chemical composition of the essential oil of marjoram (Origanum majorana L.) from Reunion Island. Food Chem 66, 143-145.
8. Mohamed M, Saad H & Abd El Khalek M (2008) Daily consumption of marjoram oil improves the health status of patients with asthma. Pak J Nutr 7, 312-316.
9. Rau O, Wurglics M, Dingermann T et al., (2006) Screening of herbal extracts for activation of the human peroxisome proliferator-activated receptor. Pharmazie 61, 952-956.
10. Bhatia V & Viswanathan P (2006) Insulin resistance and PPAR insulin sensitizers. Curr Opin Investig Drugs 7, 891-897.
11. Ahmed L, Ramadan R & Mohamed R (2009) Biochemical and histopathological studies on the water extracts of marjoram and chicory herbs and their mixture in obese rats. Pak J Nutr 8, 1581-1587.
12. Pimple BP, Kadam PV & Patil MJ (2012) Ulcer healing properties of different extracts of Origanum majorana in streptozotocin-nicotinamide induced diabetic rats. Asian Pac J Trop Dis 2, 312-318.
13. Vági E, Rapavi E, Hadolin M et al., (2005) Phenolic and triterpenoid antioxidants from Origanum majorana L. herb and extracts obtained with different solvents. J Agric Food Chem 53, 17-21.
14. El-Ashmawy I, Saleh A & Salama O (2007) Effects of marjoram volatile oil and grape seed extract on ethanol toxicity in male rats. Basic Clin Pharmacol Toxicol 101, 320-327.
15. Duke J (2002) Handbook of Medicinal Herbs, 2nd edn. Boca Raton, FL: CRC Press.
16. Gruenwald J, Brendler T & Jaenicke C (2000) PDR for Herbal Medicines, 2nd edn. Montvale, NJ: Medical Economics Company.
17. Broekmans FJ, Knauff E, Valkenburg O et al., (2006) PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG 113, 1210-1217.
18. Knochenhauer E, Key T, Kahsar-Miller M et al., (1998) Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 83, 3078-3082.
19. WHO (2011) Waist circumference and waist-hip ratio: report of a WHO expert consultation, Geneva, 8-11 December 2008. WHO Document Production Services, Geneva, Switzerland.
20. Parker CR (2006) Androgens throughout the life of women. In Androgen Excess Disorders in Women: Polycystic Ovary Syndrome and Other Disorders, 2nd edn. pp. 35-47 [Azziz R, Nestler JE & Dewailly D, editors]. Totowa, NJ: Humana Press Inc.
21. Stovall DW, Bailey AP & Pastore LM (2011) Assessment of insulin resistance and impaired glucose tolerance in lean women with polycystic ovary syndrome. J Womens Health (Larchmt) 20, 37-43.
22. Yildiz BO, Yarali H, Oguz H et al., (2003) Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome. J Clin Endocrinol Metab 88, 2031-2036.
23. Jensterle M, Weber M, Pfeifer M et al., (2008b) Assessment of insulin resistance in young women with polycystic ovary syndrome. Int J Gynaecol Obstet 102, 137-140.
24. Ducluzeau PH, Cousin P, Malvoisin E et al., (2003) Glucose-to-insulin ratio rather than sex hormone-binding globulin and adiponectin levels is the best predictor of insulin resistance in nonobese women with polycystic ovary syndrome. J Clin Endocrinol Metab 88, 3626-3631.
25. Legro RS, Finegood D & Dunaif A (1998) A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 83, 2694-2698.
26. Ghazeeri G, Kutteh WH, Bryer-Ash M et al., (2003) Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 79, 562-566.
27. Jensterle M, Sebestjen M, Janez A et al., (2008a) Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome. Eur J Endocrinol 159, 399-406.
28. Mitkov M, Pehlivanov B & Terzieva D (2006) Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 126, 93-98.
29. Yilmaz M, Karakoç A, Törüner F et al., (2005) The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. Gynecol Endocrinol 21, 154-160.
30. Guido M, Romualdi D, Suriano R et al., (2004) Effect of pioglitazone treatment on the adrenal androgen response to corticotrophin in obese patients with polycystic ovary syndrome. Hum Reprod 19, 534-539.
31. Ortega-González C, Luna S, Hernández L et al., (2005) Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab 90, 1360-1365.
32. Fecka I & Turek S (2008) Determination of polyphenolic compounds in commercial herbal drugs and spices from Lamiaceae: thyme, wild thyme and sweet marjoram by chromatographic techniques. Food Chem 108, 1039-1053.
33. Ding L, Jin D & Chen X (2010) Luteolin enhances insulin sensitivity via activation of PPARγ transcriptional activity in adipocytes. J Nutr Biochem 21, 941-947.
34. Vanithadevi B & Anuradha C (2008) Effect of rosmarinic acid on insulin sensitivity, glyoxalase system and oxidative events in liver of fructose-fed mice. Int J Diabetes Metab 16, 35-44.